Drug pricing has become a hot topic. Maybe I have become sensitized to it, but it seems like there is something about the cost of pharmaceuticals everywhere I turn – in medical journals, online discussion groups and mainstream news outlets. Just this past week, the front page story in the business section of the New York Times ran a long profile of a pharmaceutical executive that centered on his company’s controversial pricing practices. The article mentioned that pricing is now generating lawsuits and potential Congressional action.
Why all the attention? I am guessing (really – just guessing) that there are a few reasons.